| Sep 22 |
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
|
| Sep 21 |
TG Therapeutics Inc (TGTX): Short Seller Sentiment is Bearish
|
| Sep 19 |
Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock?
|
| Sep 18 |
Evaluating TG Therapeutics: Insights From 4 Financial Analysts
|
| Sep 18 |
Indexes Move Quietly Ahead Of Fed Decision; Google Stock Rises 6th Straight Day On Victory In EU Spat (Live Coverage)
|
| Sep 18 |
IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug
|
| Sep 18 |
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
|
| Sep 18 |
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
|
| Sep 6 |
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
|
| Sep 6 |
Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
|
